Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival-Reference-Cited by-同舟云学术

Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival

Published:2021-03-02 Issue:9 Volume:35 Page:2592-2601
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Abu-Zeinah Ghaith,Krichevsky Spencer,Cruz Tatiana,Hoberman Gabriela,Jaber Diana,Savage Niamh,Sosner Claudia,Ritchie Ellen K.,Scandura Joseph M.^ORCID,Silver Richard T.^ORCID

Funder

Clinical & Translational Science Center (CTSC) of Weill Cornell and the National Center for Advancing Translational Sciences (NCATS)

David L. Johns Family of the Cancer Research & Treatment Fund

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01183-8.pdf

Reference34 articles.

1. Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2726–31.

2. Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168–81.

3. Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, et al. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol. 2017;6:30.

4. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107:451–8.

5. Kiladjian J-J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

2. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera;Journal of Clinical Medicine;2024-08-22

3. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis;Annals of Hematology;2024-08-15

4. What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?;Expert Opinion on Pharmacotherapy;2024-08-12

5. SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?;Clinical Lymphoma Myeloma and Leukemia;2024-08